相似文献
1
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.
Nat Rev Cancer. 2015 Nov;15(11):668-79. doi: 10.1038/nrc4019.
2
Patient groups that fimbriectomy could reduce high grade serous ovarian cancer incidence.
Gynecol Oncol. 2013 Jan;128(1):151-152. doi: 10.1016/j.ygyno.2012.10.019. Epub 2012 Oct 23.
3
Clinicopathological and prognostic factor analyses of primary fallopian tube carcinoma and high-grade serous ovarian cancer: a single-institution retrospective study.
World J Surg Oncol. 2025 Jan 4;23(1):8. doi: 10.1186/s12957-024-03636-7.
4
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.
Lancet Oncol. 2013 Aug;14(9):853-62. doi: 10.1016/S1470-2045(13)70253-5. Epub 2013 Jul 9.
5
CT-based radiomic prognostic vector (RPV) predicts survival and stromal histology in high-grade serous ovarian cancer: an external validation study.
Eur Radiol. 2025 Jun;35(6):3110-3119. doi: 10.1007/s00330-024-11267-5. Epub 2024 Dec 11.
6
Predictors of Long-Term Survival among High-Grade Serous Ovarian Cancer Patients.
Cancer Epidemiol Biomarkers Prev. 2019 May;28(5):996-999. doi: 10.1158/1055-9965.EPI-18-1324. Epub 2019 Apr 9.
7
Should All Cases of High-Grade Serous Ovarian, Tubal, and Primary Peritoneal Carcinomas Be Reclassified as Tubo-Ovarian Serous Carcinoma?
Int J Gynecol Cancer. 2015 Sep;25(7):1201-7. doi: 10.1097/IGC.0000000000000477.
8
High expression of phosphoglycerate dehydrogenase predicts poor outcome in patients with high-grade serous ovarian cancer.
Oncologist. 2024 Sep 6;29(9):e1231-e1234. doi: 10.1093/oncolo/oyae161.
9
Genomic Rearrangement Signatures and Clinical Outcomes in High-Grade Serous Ovarian Cancer.
J Natl Cancer Inst. 2018 Mar 1;110(3):265-72. doi: 10.1093/jnci/djx176.
10
The clinical characteristics and outcomes of cases with pure ovarian clear cell, mixed type and high-grade serous adenocarcinoma.
Arch Gynecol Obstet. 2015 Oct;292(4):923-9. doi: 10.1007/s00404-015-3699-9. Epub 2015 Apr 9.
引用本文的文献
1
A new generation of N-heterocyclic carbene (NHC) gold-selenolato complexes as potent anticancer agents: distinct synthetic routes and evaluation in 2D and 3D cancer models.
Chem Sci. 2025 Aug 19. doi: 10.1039/d5sc04490a.
2
PD-1 NK cell subsets in high grade serous ovarian cancer: an indicator of disease severity and a target for combined immune-checkpoint blockade.
J Exp Clin Cancer Res. 2025 Aug 29;44(1):258. doi: 10.1186/s13046-025-03508-2.
3
ADAMTS2 mediates epithelial‒mesenchymal transition and inflammation in high-grade serous ovarian cancer: a study based on bioinformatic analyses and experiments.
BMC Cancer. 2025 Aug 26;25(1):1376. doi: 10.1186/s12885-025-14649-0.
4
The chemotherapy-induced senescence-associated secretome promotes cell detachment and metastatic dissemination through metabolic reprogramming.
bioRxiv. 2025 Aug 12:2023.12.02.569652. doi: 10.1101/2023.12.02.569652.
5
Activated MAFB in ovarian cancer promotes cytoskeletal remodeling and immune microenvironment suppression by interfering with m6A modifications through WTAP competition.
Oncogene. 2025 Aug 12. doi: 10.1038/s41388-025-03522-w.
6
RB1 expression and HR proficiency define a poor prognosis subtype of high grade serous ovarian cancer.
Sci Rep. 2025 Aug 12;15(1):29523. doi: 10.1038/s41598-025-15156-9.
7
Integrative single-cell and exosomal multi-omics uncovers SCNN1A and EFNA1 as non-invasive biomarkers and drivers of ovarian cancer metastasis.
Front Immunol. 2025 Jul 25;16:1630794. doi: 10.3389/fimmu.2025.1630794. eCollection 2025.
8
Comparative proteomic analysis of the ECM composition of the human omentum and mesentery, the main sites of ovarian cancer metastasis.
bioRxiv. 2025 Jul 31:2025.07.28.667199. doi: 10.1101/2025.07.28.667199.
9
KLF5-regulated ZDHHC8 reduces chemosensitivity in high-grade serous ovarian cancer through β-catenin signaling.
Sci Rep. 2025 Jul 18;15(1):26176. doi: 10.1038/s41598-025-11845-7.
10
Construction of prognostic scoring model for ovarian cancer based on deep learning algorithm.
Discov Oncol. 2025 Jul 1;16(1):1228. doi: 10.1007/s12672-025-03011-2.
本文引用的文献
1
Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours.
Nat Commun. 2015 Jun 17;6:7419. doi: 10.1038/ncomms8419.
2
Whole-genome characterization of chemoresistant ovarian cancer.
Nature. 2015 May 28;521(7553):489-94. doi: 10.1038/nature14410.
3
Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening.
J Clin Oncol. 2015 Jun 20;33(18):2062-71. doi: 10.1200/JCO.2014.59.4945. Epub 2015 May 11.
4
Cancer: A most exceptional response.
Nature. 2015 Apr 16;520(7547):389-93. doi: 10.1038/520389a.
5
The ovary is an alternative site of origin for high-grade serous ovarian cancer in mice.
Endocrinology. 2015 Jun;156(6):1975-81. doi: 10.1210/en.2014-1977. Epub 2015 Mar 27.
6
Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.
J Clin Oncol. 2015 Apr 20;33(12):1397-406. doi: 10.1200/JCO.2014.58.8848. Epub 2015 Mar 16.
7
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Science. 2015 Apr 3;348(6230):124-8. doi: 10.1126/science.aaa1348. Epub 2015 Mar 12.
8
Artificial Intelligence Systems as Prognostic and Predictive Tools in Ovarian Cancer.
Ann Surg Oncol. 2015 Nov;22(12):3970-5. doi: 10.1245/s10434-015-4475-6. Epub 2015 Mar 10.
9
Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis.
PLoS Med. 2015 Feb 24;12(2):e1001789. doi: 10.1371/journal.pmed.1001789. eCollection 2015 Feb.
10
A framework for a personalized surgical approach to ovarian cancer.
Nat Rev Clin Oncol. 2015 Apr;12(4):239-45. doi: 10.1038/nrclinonc.2015.26. Epub 2015 Feb 24.
Zotero 插件